SCHEMBL2657012

SCHEMBL2657012

CC(C)(C)OC(=O)N1CCCC(C=O)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.57
EPHX1 P07099 1/20 0.51
RECQL P46063 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR119 Q8TDV5 3/20 0.45
HCAR1 Q9BXC0 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23826030 0.97 HPGD (0.56) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL227336 0.94 HPGD (0.55) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL27618591 0.89 GPR119 (0.52) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1992277 0.88 MEN1 (0.52) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL641613 0.88 MEN1 (0.52) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL192730 0.88 MEN1 (0.52) HPGDEPHX1RECQLUSP2SMN1; SMN2
Dimethyl Sulfoxide SCHEMBL7366526 0.86 HPGD (0.49) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL31270977 0.85 HPGD (0.48) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL35457 0.84 HPGD (0.49) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL35456 0.84 HPGD (0.49) HPGDEPHX1RECQLUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 US disclosed
EP-4688776-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN Acerta Pharma B.V. (NL) 2026-02-11 EP disclosed
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA BV (NL) 2025-11-27 US disclosed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 EP disclosed
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 US disclosed
WO-2025137640-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-26 WO disclosed
WO-2025111513-A1 COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY NURIX THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 US disclosed
US-20250032454-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2025-01-30 US disclosed
US-8362037-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2013-01-29 US disclosed
WO-2012135113-A2 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-10-04 WO disclosed
CN-102574865-A Spirocyclic derivatives as histone deacetylase inhibitors DAC S R I 2012-07-11 CN disclosed
US-8044206-B2 Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl ASTELLAS PHARMA INC. (JP) 2011-10-25 US disclosed
US-8044206-B2 Nitrogen—containing heterocyclic derivatives having 2,6-disubstituted styryl ASTELLAS PHARMA INC. (JP) 2011-10-25 US disclosed
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPPHARMA INC. (US) 2010-04-29 US disclosed
EP-2173745-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2010-04-14 EP disclosed
WO-2008118718-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2008-10-02 WO disclosed
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. 2007-05-03 US disclosed
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM HPGD 583/4885EPHX1 2152/4885RECQL 2/4885
US-20100105659-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 HPGD 704/4885EPHX1 4374/4885RECQL 2971/4885
US-20070099956-A1 Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl SCN1B, CACNA1B, SCN2A HPGD 752/4885EPHX1 4114/4885RECQL 3474/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 HPGD 2427/4885EPHX1 4184/4885RECQL 2122/4885
US-20250032454-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A HPGD 1669/4885EPHX1 2299/4885RECQL 2695/4885
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 HPGD 4555/4885EPHX1 4839/4885RECQL 3790/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 HPGD 4555/4885EPHX1 4839/4885RECQL 3790/4885
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 HPGD 670/4885EPHX1 2671/4885RECQL 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.